

Gang Xiao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9633799/publications.pdf>

Version: 2024-02-01

47
papers

1,241
citations

759233

12
h-index

552781

26
g-index

53
all docs

53
docs citations

53
times ranked

2437
citing authors

#	ARTICLE	IF	CITATIONS
1	Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. <i>Nature</i> , 2019, 567, 414-419.	27.8	452
2	Metabolic gatekeeper function of B-lymphoid transcription factors. <i>Nature</i> , 2017, 542, 479-483.	27.8	175
3	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 27, 409-425.	16.8	109
4	Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15419-15424.	7.1	95
5	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. <i>Cell</i> , 2018, 173, 470-484.e18.	28.9	89
6	Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017, 8, 978.	12.8	58
7	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. <i>Nature</i> , 2020, 588, 491-497.	27.8	57
8	Regulation of Tcrb recombination ordering by c-Fos-dependent RAG deposition. <i>Nature Immunology</i> , 2008, 9, 794-801.	14.5	55
9	Signalling input from divergent pathways subverts B cell transformation. <i>Nature</i> , 2020, 583, 845-851.	27.8	37
10	High-resolution characterization of gene function using single-cell CRISPR tiling screen. <i>Nature Communications</i> , 2021, 12, 4063.	12.8	23
11	Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia. <i>Genes and Development</i> , 2019, 33, 1265-1279.	5.9	17
12	Downregulation of the transcription factor KLF4 is required for the lineage commitment of T cells. <i>Cell Research</i> , 2011, 21, 1701-1710.	12.0	14
13	Metabolic Gatekeepers of Pathological B Cell Activation. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 323-349.	22.4	10
14	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	10
15	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1820-1835.	4.1	9
16	c-Fos enhances the survival of thymocytes during positive selection by upregulating Bcl-2. <i>Cell Research</i> , 2009, 19, 340-347.	12.0	6
17	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1434-1434.	1.4	6
18	Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies. <i>Blood</i> , 2018, 132, 547-547.	1.4	3

#	ARTICLE	IF	CITATIONS
19	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. Blood, 2016, 128, 4088-4088.	1.4	2
20	IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation. Blood, 2018, 132, 552-552.	1.4	2
21	LGR5 Mediates Positive B-Cell Selection and is Critical for Survival of Normal and Transformed B Cells. Experimental Hematology, 2018, 64, S59-S60.	0.4	1
22	IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 788-788.	1.4	1
23	Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia. Blood, 2013, 122, 349-349.	1.4	1
24	PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia. Blood, 2016, 128, 1056-1056.	1.4	1
25	Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis. Blood, 2019, 134, 2782-2782.	1.4	1
26	Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions. Blood, 2019, 134, 746-746.	1.4	1
27	Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. Blood, 2013, 122, 72-72.	1.4	0
28	BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3570-3570.	1.4	0
29	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 284-284.	1.4	0
30	Divergent Lineage-Specific Functions of PP2A in Chronic Phase CML and Lymphoid Blast Crisis. Blood, 2014, 124, 3128-3128.	1.4	0
31	Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation. Blood, 2015, 126, 1875-1875.	1.4	0
32	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. Blood, 2015, 126, 556-556.	1.4	0
33	Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2771-2771.	1.4	0
34	Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation. Blood, 2016, 128, 437-437.	1.4	0
35	BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. Blood, 2016, 128, 438-438.	1.4	0
36	Abstract 93: Transcriptional control of glucocorticoid responses in leukemia. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
37	PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases. Blood, 2017, 130, 882-882.	1.4	0
38	Abstract 2983: CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies. , 2018, , .		0
39	Abstract 368: B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignancies. , 2018, , .		0
40	Abstract 4515: Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignancies. , 2018, , .		0
41	Abstract 5469: RAS and STAT5 pathway lesions are mutually exclusive in B-cell malignancies through mechanisms of biochemical cross-inhibition. , 2018, , .		0
42	CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies. Blood, 2018, 132, 776-776.	1.4	0
43	Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling. Blood, 2018, 132, 1336-1336.	1.4	0
44	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. Blood, 2019, 134, 393-393.	1.4	0
45	Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL. Blood, 2019, 134, 3785-3785.	1.4	0
46	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. Blood, 2019, 134, 1239-1239.	1.4	0
47	Lgr5 Functions As a Critical Negative Regulator of Wnt/ β 2-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation. Blood, 2019, 134, 748-748.	1.4	0